^
    21h
    Neo ReNi II: A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Melanoma Institute Australia | Trial completion date: Jan 2036 --> Oct 2035
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • NRAS mutation • NRAS wild-type
    |
    Opdualag (nivolumab/relatlimab-rmbw)
    1d
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Active, not recruiting, Boehringer Ingelheim | Trial completion date: May 2026 --> Feb 2026
    Trial completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    2d
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (clinicaltrials.gov)
    P2, N=93, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Phase classification: P1/2 --> P2
    Trial completion • Phase classification
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    2d
    Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Wisconsin, Madison | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    melphalan • Opdualag (nivolumab/relatlimab-rmbw) • Melblez Kit (melphalan hepatic delivery system) • relatlimab (BMS-986016)
    5d
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    8d
    Abscopal Effect Induced by LAG-3/PD-1 Inhibition and Radiation Therapy in Metastatic Acral Melanoma: A Case Report. (PubMed, Case Rep Oncol)
    Relatlimab, a LAG-3 inhibitor, in combination with nivolumab, a PD-1 inhibitor, has recently emerged as a dual ICI strategy targeting T-cell exhaustion. This case illustrates the potential synergistic effect of sequential LAG-3/PD-1 inhibition followed by radiation therapy in eliciting systemic immune activation in AM. It represents the first reported instance of an abscopal effect associated with relatlimab-based immunotherapy, suggesting that strategic sequencing of immunotherapy and radiation may be critical in overcoming immune resistance in this challenging melanoma subtype.
    Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    10d
    NOBLE: Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer. (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, National Health Research Institutes, Taiwan
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • cisplatin • gemcitabine • relatlimab (BMS-986016)
    11d
    CLeAR: Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Virginia Commonwealth University
    New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    15d
    HARMONY LUNG-2: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=950, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    15d
    HARMONY LUNG-1: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=850, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    17d
    KEYFORM-008: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) (clinicaltrials.gov)
    P2, N=203, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • favezelimab/pembrolizumab (MK-4280A)
    21d
    A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, University of Chicago
    New P2 trial
    |
    carboplatin • paclitaxel • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)